Drugs / 131I-rituximab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01678417 | Jun 2012 → Jun 2017 | non-Hodgkin lymphoma | Korea Cancer Center Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01676558 | Jun 2012 → Jun 2016 | relapsed/refractory diffuse large B-cell lymphoma | Korea Cancer Center Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01678404 | Oct 2011 → Sep 2014 | marginal zone lymphoma | Korea Cancer Center Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131I-rituximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01678404 ↗ |
| Modality | Other / unclassified | “radioimmunotherapy using 131I-rituximab” NCT01676558 ↗ |